LY-518674 - CAS 425671-29-0
Catalog number: 425671-29-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +/- 15% elevation at optimum dose.
Solid powder
2-(4-(3-(2,5-dihydro-1-((4-methylphenyl)methyl)-5-oxo-1H-1,2,4-triazol-3-yl)propyl)phenoxy)-2-methyl-Propanoic acid;
Soluble in DMSO
Store at -20 °C
Peroxisome proliferator-activated receptor alpha agonists
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Boiling Point:
575.852ºC at 760 mmHg
Canonical SMILES:
Current Developer:
Eli Lilly; Ligand Pharmaceuticals
1.Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
Hossain MA;Tsujita M;Gonzalez FJ;Yokoyama S J Cardiovasc Pharmacol. 2008 Mar;51(3):258-66. doi: 10.1097/FJC.0b013e3181624b22.
Fibric acid-shaped drugs raise high-density lipoprotein (HDL) cholesterol by upregulating the HDL-related genes through activating peroxisome proliferater activated receptor (PPAR)-alpha. We investigated the effects of fibrates to induce expression of adenosine triphosphate-binding cassette transporter A1 (ABCA1) and increase HDL biogenesis in hepatocytes. Fenofibrate, bezafibrate, gemfibrozil, and LY518674 were tested for HepG2 cells and primary-cultured mouse hepatocytes. All the compounds examined increased ABCA1 expression and HDL biogenesis dependent on PPARalpha in association with the liver X receptor alpha upregulation. While fenofibrate and LY518674 showed exclusive dependency on PPARalpha for these activities, bezafibrate and gemfibrozil exhibited dependency on PPARbeta/delta and PPARgamma as well. On the other hand, cholesterol-enrichment of HDL may involve PPARgamma for fenofibrate and bezafibrate, and PPARbeta/delta for the fibrates examined except for bezafibrate. We concluded that fibrates enhance expression of ABCA1 in hepatocytes to contribute to increase of the HDL biogenesis in a PPAR-dependent manner, whether exclusively or nonexclusively on PPARalpha.
2.Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Khera AV;Millar JS;Ruotolo G;Wang MD;Rader DJ Eur Heart J. 2015 Nov 14;36(43):3020-2. doi: 10.1093/eurheartj/ehv291. Epub 2015 Jun 25.
AIMS: ;Fibrate medications weakly stimulate the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and are currently employed clinically in patients with dyslipidaemia. The potent and selective agonist of PPAR-α LY518674 is known to substantially increase apolipoprotein A-I (apoA-I) turnover without major impact on steady-state levels of apoA-I or high-density lipoprotein-cholesterol (HDL-C). We sought to determine whether therapy with a PPAR-α agonist impacts cholesterol efflux capacity, a marker of HDL function.;METHODS AND RESULTS: ;Cholesterol efflux capacity was measured at baseline and after 8 weeks of therapy in a randomized, placebo-controlled trial involving participants with metabolic syndrome treated with either LY518674 100 μg daily (n = 13) or placebo (n = 15). Efflux capacity assessment was quantified using a previously validated ex vivo assay that measures the ability of apolipoprotein-B depleted plasma to mobilize cholesterol from macrophages. LY518674 led to a 15.7% increase from baseline (95% CI 3.3-28.1%; P = 0.02, P vs. placebo = 0.01) in efflux capacity. The change in apoA-I production rate in the active treatment arm was strongly linked to change in cholesterol efflux capacity (r = 0.
3.Gateways to clinical trials.
Tomillero A;Moral MA Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408.
(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine, Denosumab, Desloratadine, DMXB-Anabaseine, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Eicosapentaenoic acid/docosahexaenoic acid, Eletriptan, Enzastaurin hydrochloride, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumarate, Fulvestrant; Gefitinib, GM-CSF DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human Fibroblast Growth Factor 1, Hypericin-PVP; Icatibant acetate, Iclaprim, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-IL-2, Lapuleucel-T, Laropiprant, Liposomal doxorubicin, LP-261, Lumiracoxib, LY-518674; MDV-3100, MGCD-0103, Mirabegron, MyoCell; NASHA/Dx, Niacin/laropiprant; O6-Benzylguanine, Ocrelizumab, Olmesartan medoxomil, Omalizumab; P-276-00, Paclitaxel nanoparticles, Paclitaxel nanoparticles, Padoporfin, Paliperidone, PAN-811, Pegaptanib octasodium, Pegfilgrastim, Pemetrexed disodium, PF-00299804, Pimecrolimus, Prasugrel, Pregabalin; Reolysin, Rimonabant, Rivaroxaban, Rosuvastatin calcium; Satraplatin, SCH-697243,Selenite sodium, Silodosin, Sorafenib, Sunitinib malate; Talarozole, Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; Xience V; Zotarolimus-eluting stent.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PPAR Products

CAS 331741-94-7 Muraglitazar

(CAS: 331741-94-7)

Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).

SR 1664
(CAS: 1338259-05-4)

SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...

CAS 824932-88-9 GFT505

(CAS: 824932-88-9)

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. It induces resolution of nonalco...

CAS 622402-22-6 GW-590735

(CAS: 622402-22-6)

GW-590735 is a potent and selective agonist of PPARα. Its EC50 value is 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivit...

CAS 35661-60-0 NPC 15199

NPC 15199
(CAS: 35661-60-0)

NPC 15199 is an amino acid derivative. It is also one of the novel PPARγ ligands that can reduce osteoclasts differentiation through activating PPARγ.

CAS 317318-84-6 GW0742

(CAS: 317318-84-6)

GW0742 is a potent and highly selective PPARβ/δ agonist, with IC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.

CAS 539813-69-9 PPAR agonist 1

PPAR agonist 1
(CAS: 539813-69-9)

An agonist of PPAR α and PPAR γ

CAS 863405-60-1 JW74

(CAS: 863405-60-1)

JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...

CAS 425671-29-0 LY-518674

(CAS: 425671-29-0)

LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...

CAS 22978-25-2 GW9662

(CAS: 22978-25-2)

GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell ...

CAS 49562-28-9 Fenofibrate

(CAS: 49562-28-9)

Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...

CAS 41859-67-0 Bezafibrate

(CAS: 41859-67-0)

Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...

CAS 196808-24-9 GW1929

(CAS: 196808-24-9)

A potent, tyrosine-based peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC50 = 13 nM for murine receptor and 6.2 nM for human receptor in cell-ba...

FH535 sodium salt

FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...

CAS 251565-85-2 Tesaglitazar

(CAS: 251565-85-2)

Tesaglitazar is a dual-acting agonist of PPARα/γ (IC50 = 0.35 and 3.8 μM for PPARγ and PPARα, respectively). It reduces insulin resistance in obese Zucker rats ...

CAS 122320-73-4 Rosiglitazone

(CAS: 122320-73-4)

Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipoc...

CAS 213411-84-8 BM152054

(CAS: 213411-84-8)

BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.

CAS 1393371-39-5 MHY 908

MHY 908
(CAS: 1393371-39-5)

MHY 908 is a dual PPARα/γ agonist and a melanogenesis inhibitor that suppresses mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 exhibits more potent a...

CAS 810677-36-2 PPARα-MO-1

(CAS: 810677-36-2)

A potent PPARα modulator

CAS 317318-70-0 GW501516

(CAS: 317318-70-0)

GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.

Chemical Structure

CAS 425671-29-0 LY-518674

Quick Inquiry

Verification code

Featured Items